Advanced Accelerator Applications
A Novartis Company

MedTalks
AWARENESS. INSIGHT. ACTION.

MedTalks is a promotional Advanced Accelerator Applications initiative.

LUTATHERA®
Lutetium (^{177}Lu) oxodotreotide

Lutathera® (Lutetium (^{177}Lu) oxodotreotide) is indicated for the treatment of unresectable or metastatic, progressive, well differentiated (G1 and G2), somatostatin receptor positive gastroenteropancreatic neuroendocrine tumours (GEP-NETs) in adults.[1]

Taking a closer look at NETTER-1 OS

DATE: 12th July 2021
TIME: 18:00

This event is organized and funded by Advanced Accelerator Applications International S.A., a Novartis company, and is intended only for Spanish, German, and UK HCPs. In registering in the event, you acknowledge that you are located in one of these countries. AAA reserves the right to refuse attendance to the event.

We are very pleased to share the agenda and speaker bios for our post-ASCO medical expert led webinar. This event is not to be missed if you want to find out more about NETTER-1 - LUTATHERA®'s pivotal Phase III trial with a median follow-up of over 6 years,[2-3] including the 5-year OS data, safety data and the clinical implications this can have for your GEP-NET patients.

Webinar agenda:

REGISTER NOW
CLICK HERE

18:00 - 18:10	**Introduction**	Prof. Dr. Marianne Pavel
18:10 - 18:20	**NETTER-1** Trial design and interim analysis	Dr. Enrique Grande
18:20 - 18:35	**OS data** Final analysis: overall survival results	Prof. Dr. Marianne Pavel
18:35 - 18:45	**Safety** Short and long-term	Prof. Valerie Lewington
18:45 - 18:55	**Live Q&A**	All
18:55 - 19:00	**Close**	Prof. Dr. Marianne Pavel

Meet the speakers:

Dr. Enrique Grande is head of the Medical Oncology Department and Director of Research at MD Anderson Cancer Center Madrid as well as a member of the board of directors of the Spanish Task Force Group on Neuroendocrine Tumors (GEP-NETs). He is a NETTER-1 trial investigator and has led more than 200 publications in international peer review journals.

Prof. Dr. Marianne Pavel is a Senior Physician and Chair of Endocrinology at the Friedrich-Alexander University of Erlangen, Germany. She is chair of the ENETS society and a leading author on NET treatment guidelines. She is also a NETTER-1 investigator and internationally recognised NET expert.

Prof. Valerie Lewington is the Chair of Nuclear Medicine at King's College London and winner of the BNMS Roll of Honour. In parallel to innovative research in radionuclide therapy, she plays a major role in education by running the MSc programme in nuclear medicine at King's.

REGISTER NOW
CLICK HERE

To find out more information on neuroendocrine tumours and RLT please click here to visit the RLThub.co.uk

PRESCRIBING INFORMATION

References: 1. LUTATHERA® Summary of Product Characteristics. January 2021. Available at: https://www.ema.europa.eu/en/documents/product-information/lutathera-epar-product-information_en.pdf. Accessed May 2021. **2.** Strosberg J, El-Haddad G, Wolin E et al. Phase 3 trial of 177Lu-dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017; 376(2): 125–135. **3.** Strosberg J, Caplin M, Kunz P et al. Abstract 411 Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors. J Clin Oncol. 2021; 39 (suppl 15).

AAA-Lu177-UK-1107

Date of preparation: July 2021